Mounjaro (tirzepatide) is a dual GIP and GLP 1 agonist FDA approved for Type 2 diabetes. Head to head trial data shows it produces larger weight loss than semaglutide. The SURMOUNT trial program is the most cited data source for tirzepatide timelines.
This guide walks through each phase of how Mounjaro works, factors that change your individual timeline, and how meal delivery supports tirzepatide users.
Appetite suppression begins within the first week at 2.5 mg. Tirzepatide acts on both GLP 1 and GIP receptors which typically produces stronger appetite suppression than semaglutide alone. Most users describe smaller portions and reduced hunger within 5 to 10 days. The 2.5 mg starting dose is a tolerance ramp and weight loss is small in this phase (1 to 4 pounds).
Significant weight loss begins after dose escalation to 5 mg at week 5. By week 12 average loss in SURMOUNT trials was 8 to 12 percent of body weight on the 10 mg dose. Loss continues through dose climbs to 12.5 and 15 mg. Side effects often peak in these escalation phases.
Full effect is reached at the 15 mg maintenance dose, typically around week 21. SURMOUNT 1 showed average 20.9 percent body weight loss at 72 weeks. Plateaus are common after month 9 to 12 and often resolve with continued behavior reinforcement or dose adjustment.
| Week | Dose | Typical effect |
|---|---|---|
| Weeks 1 to 4 | 2.5 mg weekly | Tolerance ramp. Appetite drops. Weight loss 1 to 4 pounds. |
| Weeks 5 to 8 | 5 mg weekly | Therapeutic dose. Weight loss 1 to 2 pounds per week. |
| Weeks 9 to 12 | 7.5 mg weekly | Continued loss. Side effects often peak here. |
| Weeks 13 to 16 | 10 mg weekly | Common maintenance dose for many patients. |
| Weeks 17 to 20 | 12.5 mg weekly | Climbing to full dose. |
| Weeks 21+ | 15 mg weekly (maintenance) | Full effect. Average 20.9 percent loss at 72 weeks. |
Mounjaro users often need help maintaining adequate nutrition during the strong appetite suppression at higher doses. Meal delivery provides consistent protein when appetite is unpredictable.
Full ranking at our GLP 1 meal delivery hub.
Appetite suppression starts within the first week at 2.5 mg. Measurable weight loss begins at weeks 4 to 8. Full therapeutic effect at 15 mg maintenance is reached around week 21.
SURMOUNT 1 trial data shows average 8 to 12 percent body weight loss at week 12, and 20.9 percent at 72 weeks on 15 mg. Loss rate is 1 to 2 pounds per week during escalation for most patients.
Yes for most patients. Head to head trials show tirzepatide produces larger weight loss than semaglutide on average. The dual receptor action (GIP + GLP 1) is more effective than GLP 1 alone.
Most users plateau at month 9 to 14 on a stable dose. Plateaus typically resolve with continued behavior reinforcement, dietary refinement, or dose adjustment.
SURMOUNT 1 average is 20.9 percent body weight loss at 72 weeks on the 15 mg maintenance dose. Some patients lose more, some less. Higher BMI usually means more pounds lost.
Common reasons: still escalating doses (give it 16 to 20 weeks to reach maintenance), not enough protein, poor sleep, plateau at month 9+ (often resolved by adjustment). Discuss with prescriber if no change after 16 weeks.
Answer 5 quick questions. We'll match you to the top 3 from 24 services we track.